These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 17560156)

  • 1. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
    Wilcken DE; Sim AS; Wang J; Wang XL
    Mol Genet Metab; 2007 Aug; 91(4):309-17; discussion 308. PubMed ID: 17560156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
    Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
    JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression.
    Selley ML
    J Affect Disord; 2004 Jun; 80(2-3):249-56. PubMed ID: 15207938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
    Böger RH
    J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons.
    Selley ML
    J Neurosci Res; 2004 Jul; 77(1):90-3. PubMed ID: 15197741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.
    Stühlinger MC; Tsao PS; Her JH; Kimoto M; Balint RF; Cooke JP
    Circulation; 2001 Nov; 104(21):2569-75. PubMed ID: 11714652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
    De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
    Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
    Böger RH
    Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical significance of asymmetric dimethylarginine.
    Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
    Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH; Bode-Böger SM
    Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ADMA (asymmetric dimethylarginine)--the inhibitor of nitric oxide (NO) synthesis: a new marker for vascular pathology].
    Sela BA
    Harefuah; 2005 Sep; 144(9):655-9, 675, 674. PubMed ID: 16218539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
    Yamagishi S; Ueda S; Nakamura K; Matsui T; Okuda S
    Curr Pharm Des; 2008; 14(25):2613-8. PubMed ID: 18991678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
    Baylis C
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury.
    Ferrigno A; Di Pasqua LG; Berardo C; Richelmi P; Vairetti M
    World J Gastroenterol; 2015 May; 21(17):5131-7. PubMed ID: 25954086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells.
    Wang J; Sim AS; Wang XL; Wilcken DE
    Cell Mol Life Sci; 2006 Dec; 63(23):2838-46. PubMed ID: 17075694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction.
    Jiang DJ; Jia SJ; Yan J; Zhou Z; Yuan Q; Li YJ
    Biochem Biophys Res Commun; 2006 Oct; 349(2):683-93. PubMed ID: 16959216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
    Desai A; Zhao Y; Warren JS
    Nephrol Dial Transplant; 2008 May; 23(5):1513-20. PubMed ID: 18204093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
    Toutouzas K; Riga M; Stefanadi E; Stefanadis C
    Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetric dimethylarginine, endothelial dysfunction and renal disease.
    Aldámiz-Echevarría L; Andrade F
    Int J Mol Sci; 2012; 13(9):11288-11311. PubMed ID: 23109853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.